SPRY SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

ARS Pharma Reports Third Quarter 2026 Financial Results and Business Highlights

Nov 5, 2026

8-K

ARS Pharmaceuticals Outlines Strategic Priorities and Reports Q2 2026 Financial Results

Aug 13, 2026

8-K

ARS Pharmaceuticals Announces Departure of Board Member and Chief Medical Officer

Jul 17, 2026

8-K

ARS Pharmaceuticals Announces CEO Transition

Jul 7, 2026

8-K

ARS Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 25, 2026

8-K

ARS Pharmaceuticals Reports Q1 2026 Financial Results and Commercial Progress for neffy®

May 15, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

11,500,000 Shares-

Dec 4, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 9, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 20, 2025

S-3ASR

SHARE RESALE REGISTRATION | Offering amount: $200,000,000

Jan 31, 2025

S-8

Registration

Mar 21, 2024

S-3

64,779,432 Shares Common Stock

Apr 20, 2023

S-8

Registration

Jan 17, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

Slebir John L (Reporting)

Nov 4, 2026

Slebir John L (Reporting)

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Oct 30, 2026

144

Form 144 - Report of proposed sale of securities

Oct 19, 2026

Casale Donn (Reporting)

Oct 5, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Nov 25, 2024

CORRESP

Form CORRESP - Correspondence

Nov 18, 2024

LETTER

Form UPLOAD - SEC-generated letter

Nov 7, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

May 4, 2023

CORRESP

Form CORRESP - Correspondence

May 1, 2023

LETTER

Form UPLOAD - SEC-generated letter

Apr 24, 2023

ARS Pharmaceuticals, Inc. SPRY · SEC Filings